Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...
Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026 NGN-401 has been...
ICV is a commonly used neurosurgical procedure performed across multiple therapeutic settings, including gene therapy Presentation adds to body of evidence that ICV administration...
Barchart Research What to Expect from NGNE Earnings NGNE Generated May 7, 2026 Current Price $31.26 EPS Estimate $$-1.35 Consensus Rating Strong Buy Average Move 9.72% Neurogene Reports Before the Market...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...
Presentation at ASGCT Meeting will feature ICV as a routine neurosurgical procedure that provides broad biodistribution of gene therapy to the brain and nervous system ...
Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome ...
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...